These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 16427163)

  • 1. Waning antibodies in measles and rubella vaccinees--a longitudinal study.
    Kremer JR; Schneider F; Muller CP
    Vaccine; 2006 Mar; 24(14):2594-601. PubMed ID: 16427163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
    Tischer A; Gerike E
    Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial.
    Kohler KA; Suleiman AJ; Robertson SE; Malankar P; Al-Khusaiby S; Helfand RF; Brown D; Bellini WJ; Sutter RW
    J Infect Dis; 2003 May; 187 Suppl 1():S177-85. PubMed ID: 12721911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
    Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
    J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
    King SM; Saunders EF; Petric M; Gold R
    Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immune status against measles and rubella among 4 Chilean groups of different ages].
    Valenzuela MT; Vega J; Leal I; Vicente M; Young V; Vera L; Fasce R; Ramírez E
    Rev Med Chil; 1999 Mar; 127(3):359-65. PubMed ID: 10436723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
    Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
    Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinico-immunological evaluation of a bivalent vaccine against measles and rubella].
    Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
    Minerva Pediatr; 1990 Dec; 42(12):531-6. PubMed ID: 2087226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunity against measles and rubella in Massachusetts schoolchildren.
    Orenstein WA; Herrmann K; Albrecht P; Bernier R; Holmgreen P; Bart KJ; Hinman AR
    Dev Biol Stand; 1986; 65():75-83. PubMed ID: 3556779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The national measles and rubella campaign--one year on.
    Commun Dis Rep CDR Wkly; 1995 Nov; 5(45):237. PubMed ID: 8541943
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Responses to triple viral and tetanus vaccination in HIV-infected children].
    Echeverría Lecuona J; Aldamiz-Echevarría Azuara L; Cilla Eguiluz G; Pérez Trallero E
    An Esp Pediatr; 1996 Apr; 44(4):317-20. PubMed ID: 8849078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of measles and rubella vaccination one year after the nationwide campaign in Shiraz, Iran.
    Pourabbas B; Ziyaeyan M; Alborzi A; Mardaneh J
    Int J Infect Dis; 2008 Jan; 12(1):43-6. PubMed ID: 17950020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A seroconversion study of the measles component of the MMR vaccine in adolescents of the town of Sabrosa].
    Gonçalves G; Tavares F; de Andrade HR
    Acta Med Port; 1998 Dec; 11(12):1079-84. PubMed ID: 10192981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of antibody titers after vaccination with rubella virus vaccine ("Cendehill" strain).
    Peetermans J; du Pan RM; Huygelen C
    Dev Biol Stand; 1979; 43():361-5. PubMed ID: 520683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles seroepidemiology among adolescents and young adults: response to revaccination.
    Saffar MJ; Alraza-Amiri M; Ajami A; Baba-Mahmoodi F; Khalilian AR; Vahidshahi C; Shamsizadeh A
    East Mediterr Health J; 2006 Sep; 12(5):573-81. PubMed ID: 17333796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
    J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up.
    Davidkin I; Valle M; Julkunen I
    Vaccine; 1995 Nov; 13(16):1617-22. PubMed ID: 8578851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.